Sanofi: Press Releases, Monday, December 9, 2019
Expected Submission Timeline(1)
| NMEs | |||||||||
| SAR439859 Metastatic Breast Cancer | SAR442168(**)(8) Multiple Sclerosis | SAR339375 Alport Syndrome | |||||||
| avalglucosidase alfa Pompe Disease | fitusiran Hemophilia A/B | SAR408701 2-3LNSCLC | romilkimab Systemic scleroderma | nirsevimab (9)(**) Respira. Syncytial Virus | |||||
| sutimlimab Cold Agglutinin Disease | olipudase alfa ASD(4) | efpeglenatide(**)(5) Type 2 Diabetes | venglustat ADPKD(6) | BIVV001(**)(7) Hemophilia A | SAR440340(**)(3) Atopic Dermatitis | HIV vaccine | |||
| 2019(2) | 2020(2) | 2021(2) | 2022(2) | 2023(2) and beyond | |||||
| ADDITIONAL INDICATIONS | Dupixent®(**)(3) AD 6 – 11 years old | isatuximab 2L RRMM (IKEMA) | Aubagio® Relapsing MS – Ped | isatuximab 1L Newly Diag MM Ti | Dupixent®(**)(3) AD 6 m – 5 y old | Cerdelga® Gaucher T1, ERT switch, Ped | SAR440340(**)(3) COPD | isatuximab Newly Diag MM Te | |
| cemiplimab(**)(3) 2L BCC | Shan 6 Ped hexavalent vaccine | cemiplimab(**)(3) 2L Cervical Cancer | venglustat Gaucher Type 3 | sarilumab(**)(3) Polym.Rheumatica | SAR440340(**)(3) Asthma | venglustat GBA-PD10) | |||
| Praluent®(**)(3) LDL-C reduction, HoFH | sarilumab(**)(3) Polyarticular JIA | Praluent®(**)(3) LDL-C reduction – Ped | sarilumab(**)(3) Giant Cell Arteritis | dupilumab(**)(3) Eosinophil. esophagitis | venglustat Fabry Disease | ||||
| Dupixent® (**)(3) Asthma 6 – 11 y old | cemiplimab(**)(3) 1L NSCLC | Pediatric pentavalent vaccine (Japan) | VerorabVax® (VRVg) Purified vero rabies vaccine | ||||||
| MenQuadfiTM U.S.& EU 6w+ | SP0173 Tdap booster US | ||||||||
| Lemtrada® RRMS ped | dupilumab(**)(3) COPD | ||||||||
| isatuximab 1-2L AML / ALL ped | cemiplimab(**)(3) adjuvant in CSCC | ||||||||
| cemiplimab(**)(3) + chemo 1L NSCLC | sarilumab(**)(3) Systemic Juv. Arthri | ||||||||
- Excluding Phase 1 without POC
- Projects within a specified year are not arranged by submission timing
- Developed in collaboration with Regeneron
- Acid Sphingomyelinase Deficiency
- Developed in collaboration with Hanmi
- Autosomal Dominant Polycystic Kidney Disease
- Developed in collaboration with SOBI
- Developed in collaboration with Principia
- Developed in collaboration with AstraZeneca
- Parkinson’s Disease with an associated GBA mutation
(**) Partnered and/or in collaboration – Sanofi may have limited or shared rights on some of these products